Giulia De Conti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Giulia De Conti has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- René Bernards
Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
58 shared publications - Antonio Mulero-Sánchez
SOLTI Cancer Research Group, Barcelona, Spain
53 shared publications - Roderick Leonardus Beijersbergen
Division of Molecular Carcinogenesis, The NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands
53 shared publications - Wenxin Qin
State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute & Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
53 shared publications - Alberto Villanueva
Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet del Llobregat, Barcelona, Spain
52 shared publications - Alexander van Oudenaarden
Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences), Oncode Institute
52 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Supplementary table 7: Full list of genes whose knockout was selectively toxic in the presence of LB-100 in SW-480 cells in the CRISPR-KO screen FDR smaller or equal to 0.25 and log2 fold change smaller or equal to -1 in treated/untreated comparison were criteria for hit selection.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Supplementary table 7: Full list of genes whose knockout was selectively toxic in the presence of LB-100 in SW-480 cells in the CRISPR-KO screen FDR smaller or equal to 0.25 and log2 fold change smaller or equal to -1 in treated/untreated comparison were criteria for hit selection.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Supplementary table 4: The composition of the stress-focused drug library Compounds comprising the stress-focused drug library with their respective targets.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Supplementary table 4: The composition of the stress-focused drug library Compounds comprising the stress-focused drug library with their respective targets.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S3: High N-Myc levels sensitize neuroblastoma cells to LB-100, and PP2A knockdown sensitizes CRC cells to WEE1 inhibition (A) Western blots comparing N-Myc levels in isogenic neuroblastoma models. GAPDH was used as a loading control. (B) long-term viability assays compares the toxicity of LB-100 across these neuroblastoma models. LB-100 was refreshed every 2-3 days, and the cells were grown for 10 days before fixing, staining, and imaging. (C) Western blots show the knockdown of PPP2R1A in HT-29 and SW-480 cells. GAPDH was used as a loading control. (D) Dose-response assays show the effect of Adavosertib after PPP2R1A knockdown compared to a control shRNA in HT-29 and SW-480 cells. Cell viability was estimated by resazurin fluorescence after 5 days in the presence of the drug or DMSO control. The normalized values are plotted. (E) The heat map shows all “Hallmarks” and “KEGG” molecular signatures significantly enriched by LB-100 (4 µM), calyculin A (5 nM), or okadaic acid (10 nM) in HT-29 and SW-480 cells after 8 hours. Asterisks indicate significance level (* p-value <0.05, ** p-value <0.01, *** p-value <0.001).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S3: High N-Myc levels sensitize neuroblastoma cells to LB-100, and PP2A knockdown sensitizes CRC cells to WEE1 inhibition (A) Western blots comparing N-Myc levels in isogenic neuroblastoma models. GAPDH was used as a loading control. (B) long-term viability assays compares the toxicity of LB-100 across these neuroblastoma models. LB-100 was refreshed every 2-3 days, and the cells were grown for 10 days before fixing, staining, and imaging. (C) Western blots show the knockdown of PPP2R1A in HT-29 and SW-480 cells. GAPDH was used as a loading control. (D) Dose-response assays show the effect of Adavosertib after PPP2R1A knockdown compared to a control shRNA in HT-29 and SW-480 cells. Cell viability was estimated by resazurin fluorescence after 5 days in the presence of the drug or DMSO control. The normalized values are plotted. (E) The heat map shows all “Hallmarks” and “KEGG” molecular signatures significantly enriched by LB-100 (4 µM), calyculin A (5 nM), or okadaic acid (10 nM) in HT-29 and SW-480 cells after 8 hours. Asterisks indicate significance level (* p-value <0.05, ** p-value <0.01, *** p-value <0.001).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S7: Normal tissues from the orthotopic CRC PDXs are not affected by LB-100, adavosertib, or the combination. Representative Hematoxylin & Eosin (H&E) stainings of the heart, liver, lung, and spleen from the PDOX1 PDXs treated as indicated. Original magnifications are indicated.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S7: Normal tissues from the orthotopic CRC PDXs are not affected by LB-100, adavosertib, or the combination. Representative Hematoxylin & Eosin (H&E) stainings of the heart, liver, lung, and spleen from the PDOX1 PDXs treated as indicated. Original magnifications are indicated.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S9: Single-cell RNAseq identify transcriptional signatures downregulated in CRC cells after acquired resistance to the combination of LB-100 and adavosertib UMAP representations of HT-29 (A) and SW-480 (B) cells colored by the activity scores for the indicated pathways. UMAPs colored by sample of origin from both cell lines are present of the left for reference. The boxen plots show the pathway activity scores for parental (red) and resistant (blue) cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S9: Single-cell RNAseq identify transcriptional signatures downregulated in CRC cells after acquired resistance to the combination of LB-100 and adavosertib UMAP representations of HT-29 (A) and SW-480 (B) cells colored by the activity scores for the indicated pathways. UMAPs colored by sample of origin from both cell lines are present of the left for reference. The boxen plots show the pathway activity scores for parental (red) and resistant (blue) cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S8: Acquired resistance to the combination of LB-100 and adavosertib suppressed malignant traits in CRC models (A) IncuCyte-based proliferation assays from HT-29 and SW-480 parental and resistant cells in the absence or presence of the combination (LB-100 4 µM + adavosertib 400 nM). (B) Chromosome counting and representative chromosome spreads from HT-29 and SW-480 parental and resistant cells. Nocodazole was added for 3h to block cells in mitosis. Cells were harvested by mitotic shake-off for spreading. Over 40 (HT-29 and HT-29-R) or 50 (SW-480 and SW-480-R) spreads were counted per cell line. Asterisks indicate significance level (**** p-value <0.0001) by two-tailed Mann-Whitney test. (C) Heatmaps showing the marker genes of each cluster from the scRNAseq analyses of HT-29 and SW-480 cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S8: Acquired resistance to the combination of LB-100 and adavosertib suppressed malignant traits in CRC models (A) IncuCyte-based proliferation assays from HT-29 and SW-480 parental and resistant cells in the absence or presence of the combination (LB-100 4 µM + adavosertib 400 nM). (B) Chromosome counting and representative chromosome spreads from HT-29 and SW-480 parental and resistant cells. Nocodazole was added for 3h to block cells in mitosis. Cells were harvested by mitotic shake-off for spreading. Over 40 (HT-29 and HT-29-R) or 50 (SW-480 and SW-480-R) spreads were counted per cell line. Asterisks indicate significance level (**** p-value <0.0001) by two-tailed Mann-Whitney test. (C) Heatmaps showing the marker genes of each cluster from the scRNAseq analyses of HT-29 and SW-480 cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Supplementary table 5: Stress-focused drug screens AUC differences in HT-29 cells Area Under the Curve (AUC) from each compound of the stress-focused drug screen in the presence or absence of LB-100. Compounds are ranked by the difference in the AUC between LB-100-treated and untreated samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Supplementary table 5: Stress-focused drug screens AUC differences in HT-29 cells Area Under the Curve (AUC) from each compound of the stress-focused drug screen in the presence or absence of LB-100. Compounds are ranked by the difference in the AUC between LB-100-treated and untreated samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S10: Acquired resistance to the combination of LB-100 and Adavosertib suppress anchorage-independent and tumor growth in CRC models (A) Endpoint proliferation of HT-29 and SW-480 parental and resistant cells growing attached or in anchorage-independent conditions. Cells were plated in the same density on regular or cell-repellent culture plates in the absence of drugs and grown for 5-6 days. Proliferation was addressed by CellTiter-Glo 3D® and is expressed as fold change over T0. (B) Growth curves of the individual tumors from SW-480 parental and resistant cells measured 3 times per week. The dashed line indicates the 1500 mm3 ethical sacrifice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S10: Acquired resistance to the combination of LB-100 and Adavosertib suppress anchorage-independent and tumor growth in CRC models (A) Endpoint proliferation of HT-29 and SW-480 parental and resistant cells growing attached or in anchorage-independent conditions. Cells were plated in the same density on regular or cell-repellent culture plates in the absence of drugs and grown for 5-6 days. Proliferation was addressed by CellTiter-Glo 3D® and is expressed as fold change over T0. (B) Growth curves of the individual tumors from SW-480 parental and resistant cells measured 3 times per week. The dashed line indicates the 1500 mm3 ethical sacrifice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S1: LB-100 engages stress-related, inflammatory response, and mitogenic signaling transcriptional programs in CRC cells (A) Dose-response assays show the effect of LB-100 in 7 CRC models. Cell viability was estimated by resazurin fluorescence after 5 days in the presence of the drug or DMSO control. The normalized values are plotted. (B) The heat map shows all “Hallmarks” and “KEGG” molecular signatures significantly enriched by LB-100 (4 µM) in both HT-29 and SW-480 cells in at least one of the addressed time points. Asterisks indicate significance level (* p-value <0.05, ** p-value <0.01, *** p-value <0.001)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S1: LB-100 engages stress-related, inflammatory response, and mitogenic signaling transcriptional programs in CRC cells (A) Dose-response assays show the effect of LB-100 in 7 CRC models. Cell viability was estimated by resazurin fluorescence after 5 days in the presence of the drug or DMSO control. The normalized values are plotted. (B) The heat map shows all “Hallmarks” and “KEGG” molecular signatures significantly enriched by LB-100 (4 µM) in both HT-29 and SW-480 cells in at least one of the addressed time points. Asterisks indicate significance level (* p-value <0.05, ** p-value <0.01, *** p-value <0.001)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S5: Combined toxicity of LB-100 and Adavosertib in PDAC and CCA models (A) and (B) Dose-response assays show the effect of LB-100 or Adavosertib in 4 PDAC and 4 CCA models, respectively. Cell viability was estimated by resazurin fluorescence after 5 days in the presence of the drug or DMSO control. The normalized values are plotted. (C) and (D) Long-term viability assays show 4 PDAC and 4 CCA models, respectively, treated with LB-100 or Adavosertib at the indicated concentrations. Treatments were refreshed every 2-3 days, and the cells were grown for 10-14 days before fixing, staining, and imaging. (E) and (F) IncuCyte-based proliferation assays from 4 PDAC and 4 CCA models, respectively, in the absence or presence of LB-100, Adavosertib, or the combination at the indicated concentrations.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S5: Combined toxicity of LB-100 and Adavosertib in PDAC and CCA models (A) and (B) Dose-response assays show the effect of LB-100 or Adavosertib in 4 PDAC and 4 CCA models, respectively. Cell viability was estimated by resazurin fluorescence after 5 days in the presence of the drug or DMSO control. The normalized values are plotted. (C) and (D) Long-term viability assays show 4 PDAC and 4 CCA models, respectively, treated with LB-100 or Adavosertib at the indicated concentrations. Treatments were refreshed every 2-3 days, and the cells were grown for 10-14 days before fixing, staining, and imaging. (E) and (F) IncuCyte-based proliferation assays from 4 PDAC and 4 CCA models, respectively, in the absence or presence of LB-100, Adavosertib, or the combination at the indicated concentrations.